Synthesis of bivalent β2-adrenergic and adenosine A 1 receptor ligands

Journal of Medicinal Chemistry

Volumn 51, Issue 19, 2008, Pages 6128-6137

  Karellas, Peter ^a,b   McNaughton, Michael ^a   Baker, Stephen P ^c   Scammells, Peter J ^a  

^a MONASH UNIVERSITY   (Australia)

^b Starpharma Holdings Limited   (Australia)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENYLATE CYCLASE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; LIGAND; N [2 HYDROXY 5 [1 HYDROXY 2 [4 (N 6 ADENOSINYL)BUTYLAMINO]ETHYL]PHENYL]FORMAMIDE; N [2 HYDROXY 5 [1 HYDROXY 2 [6 (N 6 ADENOSINYL)HEXYLAMINO]ETHYL]PHENYL]FORMAMIDE; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; CYCLIC AMP; FORMAMIDE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; IN VITRO STUDY; NONHUMAN; RECEPTOR AFFINITY; ANIMAL; BINDING SITE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG POTENTIATION; HAMSTER; METABOLISM; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; CARBAMATES; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMAMIDES; ISOPROTERENOL; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTOR, ADENOSINE A1; RECEPTORS, ADRENERGIC, BETA-2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 53549115957     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800613s     Document Type: Article

References (30)

1. Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J. Med. Chem. 1986, 29, 1855-1861.
2. 1B/1D receptor subtypes. Bioorg. Med. Chem. Lett. 1998, 8, 1407-1412.
3. 2 phenotypes. Selective targeting of δ-β heterodimers. J. Med. Chem. 2004, 47, 2969-2972.
4. 3 adenosine receptor agonists. J. Biol. Chem. 2000, 275, 30272-30279.
5. 1B/1D agonists. J. Med. Chem. 1996, 39, 4920-4927.
6. Portoghese, P. S.; Larson, D. L.; Yim, C. B.; Sayre, L. M.; Ronsisvalle, G.; Lipkowski, A. W.; Takemori, A. E.; Rice, K. C.; Tam, S. W. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J. Med. Chem. 1985, 28, 1140-1141.
7. Krammer, R. H.; Karpen, J. W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 1998, 395, 710-713.
8. Gilman, A. G. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 1987, 56, 615-649.
9. 6-(L-2-phenylisoproyl)adenosine and insulin on cAMP metabolism in 3T3-L1 adipocytes. Am. J. Physiol. 1987, 252, C342-C348.
10. Romano, F. D.; MacDonald, S. G.; Dobson, J. G. Adenosine receptor coupling to adenylate cyclase of rat ventricular myocyte membranes. Am. J. Physiol. 1989, 257, H1088-H1095.
11. 1 MF-2 smooth muscle cells. Mol Pharmacol. 1990, 38, 660-666.
12. Dobson, J. G.; Fenton, R. A.; Romano, F. D. Increased myocardial adenosine production and reduction of β-adrenergic contractile response in aged hearts. Circ. Res. 1990, 66, 1381-1390.
13. Suteparuk, S.; Nies, A. S.; Andros, E.; Gerber, J. G. The role of adenosine in promoting cardiac β-adrenergic subsenitivity in aging humans. J. Gerontol. 1995, 50A, B128-B134.
14. Song, Y.; Shryock, J. C.; Knot, H. J.; Belardinelli, L. Selective attenuation by adenosine of arrhythmogenic action of isoproterenol on ventricular myocytes. Am. J. Physiol.: Heart Circ. Physiol. 2001, 281, H2789-2795.
15. Jacobson, K. A.; van Galen, P. J. M.; Williams, M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem. 1992, 35, 407-422.
16. Ruffolo, R. R.; Bondinell, W.; Hieble, J. P. α- and β-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem. 1995, 38, 3681-3716.
17. Scarpace, P. J.; Baresi, L. A.; Sanford, D. A.; Abrass, I. B. Desensitization and resensitization of β-adrenergic receptors in a smooth muscle cell line. Mol. Pharmacol. 1985, 28, 495-501.
18. Kaiser, C.; Colella, D. F.; Schwartz, M. S.; Garvey, E.; Wardel, J. R., Jr. Adrenergic agents. 1. Synthesis and potential β-adrenergic agonist activity of some catecholamine analogs bearing a substituted amino functionality in the meta position. J. Med. Chem. 1974, 17, 49-57.
19. Hett, R.; Fang, Q. K.; Gao, Y.; Hong, Y.; Butler, H. T.; Nie, X.; Wald, S. A. Enantio- and diastereoselective synthesis of all four stereoisomers of formoterol. Tetrahedron Lett. 1997, 38, 1125-1128.
20. Campos, F. M.; Bosch, P.; Guerrero, A. An efficient enantioselective synthesis of (R,R)-formoterol, a potent bronchodilator, using lipases. Tetrahedron: Asymmetry 2000, 11, 2705-2717.
21. Muller, D.; Zeltser, I.; Bitan, G.; Gilon, C. Building units for N-backbone cyclic peptides. 3. Synthesis of protected Nα-(ω- aminoalkyl) amino acids and Nα-(ω-carboxyalkyl) amino acids. J. Org. Chem. 1997, 62, 411-416.
22. 2-adrenoceptor activity. Bioorg. Med. Chem. Lett. 2004, 14, 4705-4710.
23. Kumar, N.; Kiuchi, M.; Tallarico, J. A.; Schreiber, S. L. Small-molecule diversity using a skeletal transformation strategy. Org. Lett. 2005, 7, 2535-2538.
24. Yoshida, Y.; Barrett, D.; Azami, H.; Morinaga, C.; Matsumoto, S.; Matsumoto, Y.; Takasugi, H. Studies on anti-Helicobacter pylori agents. Part 1: benzyloxyisoquinoline derivatives. Bioorg. Med. Chem. 1999, 7, 2647-2666.
25. 6- disubstituted adenosines: potent and selective A, adenosine receptor agonists. Bioorg. Med. Chem. 2002, 10, 1115-1122.
26. Senanayake, C. H. Desformoterol and Process for its Preparation. U.S. Patent 5,965,622, 1999.
27. Greenwald, R. B., Zhao, H. Poly(ethylene glycol) Prodrugs: Altered Pharmacokinetics and Pharmacodynamics. In Prodrugs: Challenges and Rewards; Stella, V. J., Tilley, J. W., Eds.; Springer: Boston, 2007; pp 283-338.
28. Portoghese, P. S.; Ronsisvalle, G.; Larson, D. L.; Takemori, A. E. Synthesis and opioid antagonist potencies of nalterexamine bivalent ligands with conformationally restricted spacers. J. Med. Chem. 1986, 1650-1653.
29. Zhang, J.; Belardinelli, L.; Jacobson, K. A.; Otero, D. H.; Baker, S. P. Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart. Mol. Pharmacol. 1997, 52, 491-498.
30. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.